Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

INTRODUCTION: Semaglutide, a peptidic GLP-1 receptor agonist, has been clinically approved for treatment of type 2 diabetes mellitus and is available in subcutaneous and oral dosage form. Diabetes, insulin resistance, and obesity are responsible for the pathological manifestations of non-alcoholic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahapatra, Manoj K., Karuppasamy, Muthukumar, Sahoo, Biswa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Expert Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159769/
https://www.ncbi.nlm.nih.gov/pubmed/35650449
http://dx.doi.org/10.1007/s11095-022-03302-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159769/
https://www.ncbi.nlm.nih.gov/pubmed/35650449
http://dx.doi.org/10.1007/s11095-022-03302-1

Ejemplares similares